Exscientia Closes $100M in Series C Financing

05 Mar, 2021

Exscientia Closes $100M in Series C Financing
Photo by Asaf Gazit on Unsplash

– Exscientia is a clinical stage pharmatech company pioneering the use of artificial intelligence (AI) to design new drugs.
– Company raised 100m in Series C funding.
– The round was led by BlackRock with participation from Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.
– The company intends to use the funds for platform development towards autonomous drug design, extension of its proprietary pipeline into clinical trials and expansion of existing capabilities in biological analytics that support target selection and portfolio development.

Artificial Intelligence Biotechnology Europe Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: